Nishodna regulacija MAPK/MAK/MRK preklapajuće kinaze 1 u mononuklearnim ćelijama periferne krvi pedijatrijskih pacijenata sa tipom 1 dijabetesa melitusa

  • Miron Sopić Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Serbia
  • Ana Ninić Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Serbia
  • Barbara Ostanek Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Slovenia
  • Dragana Bojanin Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Biochemical Laboratory, Belgrade, Serbia
  • Tatjana Milenković Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Department of Endocrinology, Belgrade, Serbia
  • Jelena Munjas Department of Medical Biochemistry, Faculty of Pharmacy. University of Belgrade
  • Marija Mihajlović Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Serbia
  • Jelena Vekić Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Serbia
  • Janja Marc Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Slovenia
  • Vesna Spasojević-Kalimanovska Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Serbia
DOI: https://doi.org/10.5937/jomb0-33220
Ključne reči: Dijabetes mellitus tip 1, Mammalian target of rapamycin, MAPK/MAK/MRK prekalapajuća kinaza 1

Sažetak


Dijabetes melltus tip 1 (T1DM) predstavlja jedan od najčešćih endokrinih poremećaja kod dece. Autoreaktivnost T limoficta prema  β-ćelijama pankreasa je pod uticajem značajnih promena u njihovom metabolizmu. Mammalian target of rapamycin (mTOR) je značajan intracelularni regulator metabolizma i ćelijskog razvoja. MAPK/MAK/MRK preklapajuća kinasa 1 (MOK1) predstavlja jedan od slabo proučavanih regulatora mTOR. Cilj studije je bio da se ispita da li su nivoi iRNK MOK1 i mTOR u monunklearnim ćelijama periferne krvi pedijatrijskih pacijenata sa T1DM različiti u odnosu na zdrave ispitanike.

U ovoj studiji su učestvovala 172 adolescenta sa T1DM i 36 zdravih ispitanika koji su činili kontrolnu grupu (KG). Nivoi iRNK MOK1 i mTOR u mononuklearnim ćelijama periferne krvu su određeni kvantitativnim PCR-om.

Pacijenti sa T1DM su imali značajno niže nivoe iRNK MOK1 u odnosu na KG (P=0,018), dok razlike u nivoima iRNK mTOR nisu bile značajne (P=0,891). U grupi pacijenata sa T1DM uočena je značajna korelacija između MOK1 i godina starosti, indeksa telesne mase, nivoa triglicerida i mTOR, kao i između mTOR i indeksa telesne mase i sistolnog krvnog pritiska. Pacijenti sa T1DM koji su imali prekomernu telesnu masu imali su značajno niže vrednosti iRNK MOK1 (P=0,034) i mTOR (P=0.017) i značajno više nivoe sistolnog krvnog pritiska (P<0,001), ukupnog holesterola (P=0,001), LDL-holesterola (P=0,001) i CRP (P<0,001). Multivarijantna analiza je pokazala negativnu vezu između MOK1 i T1DM, nezavisno od pola, starosti, HDL-holesterola i CRP (OR=0,417 (95%CI: 0,175-0,997), p=0,049).

Naša studija je po prvi put ukazala na vezu između T1DM i nishodne regulacije MOK1. Takođe, nishodna regulacija mTOR i MOK1 je bila udružena sa faktorima rizika za razvoj kardiovaskularnih bolesti kod pacijenata sa T1DM prekomerne težine.

Objavljeno
2021/11/03
Broj časopisa
Vol. 41 Br. 3 (2022): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2021 Jelena Munjas

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.